Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. - Wikidata - awgldk - TriplyDB

Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism.

Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism.

http://www.wikidata.org/entity/Q33852093

about

KIBRA: A New Gateway to Learning and Memory?Evidence for an association between KIBRA and late-onset Alzheimer's disease Brain fuel metabolism, aging, and Alzheimer's disease Contributions of neuropsychology and neuroimaging to understanding clinical subtypes of mild cognitive impairment GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers APOE genotype and stress response - a mini review Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals Brain imaging in Alzheimer disease Ushering in the study and treatment of preclinical Alzheimer disease Triad of Risk for Late Onset Alzheimer's: Mitochondrial Haplotype, APOE Genotype and Chromosomal Sex Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy Neighborhood psychosocial environment, apolipoprotein E genotype, and cognitive function in older adults Energy failure: does it contribute to neurodegeneration?Functional network endophenotypes unravel the effects of apolipoprotein E epsilon 4 in middle-aged adults Biochemical assessment of precuneus and posterior cingulate gyrus in the context of brain aging and Alzheimer's disease Exercise, APOE genotype, and the evolution of the human lifespan Neuroimaging of individuals with Down’s syndrome at-risk for dementia: Evidence for possible compensatory events Imaging studies and APOE genotype in persons at risk for Alzheimer's disease.Linking brain imaging and genomics in the study of Alzheimer's disease and aging.Use of functional magnetic resonance imaging in the early identification of Alzheimer's disease.Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain.Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons.APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging.Intellectual enrichment is linked to cerebral efficiency in multiple sclerosis: functional magnetic resonance imaging evidence for cognitive reserve.The Effect of Apolipoprotein E ε4 (APOE ε4) on Visuospatial Working Memory in Healthy Elderly and Amnestic Mild Cognitive Impairment Patients: An Event-Related Potentials Study.Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible.Amyloid load in nondemented brains correlates with APOE e4.Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative Age and education effects on relationships of cognitive test scores with brain structure in demographically diverse older persons The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease.Genetic variation at a single locus and age of onset for Alzheimer's disease.Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI).Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease Cerebral blood volume in Alzheimer's disease and correlation with tissue structural integrity.Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging.Temporal lobe functional activity and connectivity in young adult APOE varepsilon4 carriers.Forebrain-dominant deficit in cerebrovascular reactivity in Alzheimer's disease.Is Alzheimer's disease a systemic disease?APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease.Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.

P2860

Q21129069-6007CB75-39B4-4340-A679-BF79C3E7F5EF Q24598464-27F92209-ECEE-47D1-AA9F-0A7F7C6D1FA0 Q24625859-A38C6861-1365-4C7F-AB53-C50920C3D833 Q24629087-F5D0A386-9C67-4F15-BDA5-9CEF83FA5846 Q24654145-10834AC7-34B6-4136-B205-BC94EA2ECD89 Q26741633-A8976712-D809-46C0-A118-CFCACC54553A Q26995405-AAB09586-6547-4B4F-B915-88226A4F4523 Q26996299-A6C5077B-A29C-40F9-B6A2-6B27A2C7545B Q27014791-485893FF-EC9B-486F-B95E-0E029C3C4798 Q28077056-75FF5548-A2DD-4CFD-9E2A-7DE764221FCA Q28282855-6D221754-F0A0-404B-A489-8B694028FDCB Q28383537-9A327FC0-2ADB-403D-B8C2-C13F97AC1746 Q28389950-D42EF262-74E9-4033-A5C8-B168D3AF5A02 Q28394313-34ED6B93-99AE-4F8C-9F97-15890D6586A4 Q28542628-64A74C66-C755-4B56-BC7B-F6B8E81A9C0B Q28657798-D23342EA-AC01-4A4E-BB0B-0D0391F54C77 Q30051683-0E004838-8894-4453-B12A-3F51764C0DE2 Q31033399-95284078-D4C2-4B1D-9704-BB469424D215 Q31108276-E5E82411-927A-428C-BBCD-4F964232ED99 Q31111440-7A8EA2E3-F878-4D7A-90F5-0BF55B476E1B Q33262303-2E0AED55-8764-4557-88EC-355C036E2D42 Q33323272-479D7BE6-7496-4EEC-9B24-2974A61D643D Q33423191-860312FE-06B6-46A1-ACB6-6EBBA09A7DA2 Q33656333-3ADE21B8-B6C7-4104-8328-82A114E0D96F Q33695116-7D56CBA4-BBE5-45BC-B43F-15B79075C1F9 Q33773031-05E01E40-C3D6-445F-BC5F-101043D6682B Q33775494-1E6A25F9-FB44-4AA4-928C-E1089F3E4A5D Q33798435-D7632DD7-3F5B-42D7-A56D-8D0689BC8A11 Q33819499-163113D7-336C-4762-AA55-C7D11EB37752 Q33841363-55AD2A11-818A-4F22-A1F5-B3B01BD30363 Q33870512-2F193167-B328-4A49-88F8-A2FD6D6EFAF7 Q33917702-2CB11CFC-4993-4AA7-849C-F495F16D9717 Q33917722-63C722EC-B0D9-4F4B-B0A1-39A65A9799C9 Q33925140-6441E530-7609-4CE0-83A7-E67B346FED26 Q33925913-12B73071-2EB6-4465-8C85-95E224D879C5 Q33940338-7FC550F8-0E28-4814-BB1E-E44EB41A0CB4 Q33959584-1626EBDA-D59D-4E92-AE72-327B3220B9F6 Q34019193-27EC762A-0F19-437C-963B-BC3781E19BD3 Q34034409-48D5495F-773B-43A6-A51A-4134BE4A4428 Q34039983-F09BE277-9B57-4112-A1AD-3CBFF570F5F1

P2860

Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism.

http://www.wikidata.org/entity/Q33852093

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Correlations between apolipopr ...... ts of regional hypometabolism.

@ast

Correlations between apolipopr ...... ts of regional hypometabolism.

@en

type

label

Correlations between apolipopr ...... ts of regional hypometabolism.

@ast

Correlations between apolipopr ...... ts of regional hypometabolism.

@en

prefLabel

Correlations between apolipopr ...... ts of regional hypometabolism.

@ast

Correlations between apolipopr ...... ts of regional hypometabolism.

@en

P1433

Q33852093-D7C52121-8DCF-41EB-BD85-A2EEA7CE5750

P1476

Q33852093-97B208B0-8E9E-4162-897A-0666B7573D49

P2093

Q33852093-08FE5BDF-F196-4929-A089-5A3D6896919E

Q33852093-6C64ABA0-AED2-4B0D-8F9E-94FA84F0EB7D

Q33852093-7AD93D28-F098-4624-8349-ECB6F9483E50

Q33852093-87A9E08B-E8E6-42D9-BBB0-38841475CE0F

Q33852093-F5FE1ABC-ECAD-4427-AFF4-507295A9D8B7

P2860

Q33852093-02F2D770-B24F-447F-A362-E4A2FD5506B0

Q33852093-042F7F4C-D2EA-4B4D-8910-9B27A3D16725

Q33852093-0B473422-0ABC-4CED-A55F-9F8D41BD0402

Q33852093-0D61945E-DDA4-480D-BA7D-8D4A59895A0B

Q33852093-10548D7F-986D-4536-85F9-3E9A0ECF1701

Q33852093-18DD231A-41AF-4025-926C-5F22CBAA5834

Q33852093-34CFA9FC-6CC4-4626-B2C9-C2FE6557ED07

Q33852093-52B6268B-B5EF-404A-8D22-BF55214A2FA1

Q33852093-539A24C2-D903-4EF3-802E-E8483B090874

Q33852093-67E9AFE7-C1E8-4A2B-80E4-BE72B585DA43

P304

Q33852093-3D901FC3-A98C-44C6-A4FC-0D90372A7F61

P31

Q33852093-138A169E-E1D3-4CE4-9C2A-F98E69E3ECFD

P356

Q33852093-AF6E5B6B-5941-4B2A-848D-59F071EDA756

P407

Q33852093-2C25987B-CBAB-418E-96D4-ED7B89F28CDD

P433

Q33852093-EE23D675-1F4C-4753-8B61-FCE22337F121

P478

Q33852093-7B70D90D-D9C7-4486-8BE1-6759FDD4990B

P50

Q33852093-0D236993-1EAA-4E2A-AAD2-8607A2BE8139

Q33852093-57A080AC-4315-469A-B849-696C3C044CA2

Q33852093-79C46060-2F7A-4D6A-8D3B-7041D3CF6C99

P577

Q33852093-55AE4D14-F357-48E5-BE9B-A2FA21AA23A5

P5875

Q33852093-20B0FF9F-4873-490B-95E7-E301279CF2F1

P698

Q33852093-75BAB5F0-3927-4A9D-AAFF-3BD41901AFCE

P932

Q33852093-1C8FC075-8290-456B-8986-02BCBE85F306

P356

PNAS.0500579102

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Correlations between apolipopr ...... ts of regional hypometabolism.

@en

P2093

Ann M Saunders

http://www.w3.org/2001/XMLSchema#string

Daniel Bandy

http://www.w3.org/2001/XMLSchema#string

David Osborne

http://www.w3.org/2001/XMLSchema#string

Gene E Alexander

http://www.w3.org/2001/XMLSchema#string

Richard J Caselli

http://www.w3.org/2001/XMLSchema#string

P2860

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

The endophenotype concept in psychiatry: etymology and strategic intentions

Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium

Apolipoprotein E: cholesterol transport protein with expanding role in cell biology

Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia

Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease.

Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease.

Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.

Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.

Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment.

P304

8299-8302

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0500579102

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

John Anthony Hardy

P577

2005-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7809144

http://www.w3.org/2001/XMLSchema#string

P698

15932949

http://www.w3.org/2001/XMLSchema#string

P932

1149416

http://www.w3.org/2001/XMLSchema#string